Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.48 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.47 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304781 | 0.95 | KMT2A (0.65) | KMT2AL3MBTL1JAK1KCNA3DRD2 | |
| SCHEMBL555251 | 0.95 | KMT2A (0.62) | KMT2AL3MBTL1JAK1KCNA3DRD2 | |
| SCHEMBL2378151 | 0.90 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KCNA3DRD2 | |
| SCHEMBL21178236 | 0.90 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KCNA3DRD2 | |
| SCHEMBL19051699 | 0.90 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KCNA3DRD2 | |
| SCHEMBL25263326 | 0.90 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KCNA3DRD2 | |
| SCHEMBL13520171 | 0.90 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KCNA3DRD2 | |
| SCHEMBL21166304 | 0.90 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KCNA3DRD2 | |
| SCHEMBL1552482 | 0.90 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KCNA3DRD2 | |
| SCHEMBL30404117 | 0.90 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KCNA3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4277901-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| WO-2022152821-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3160477-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015200680-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200680-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2011060396-A1 | ALIPHATIC AMINES BASED HETEROCYCLES USEFUL AS HIV ENTRY BLOCKERS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | KMT2A 1951/4885L3MBTL1 1148/4885JAK1 4074/4885 |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | KMT2A 60/4885L3MBTL1 1143/4885JAK1 826/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | KMT2A 1988/4885L3MBTL1 1278/4885JAK1 3890/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | KMT2A 1951/4885L3MBTL1 1148/4885JAK1 4074/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | KMT2A 1755/4885L3MBTL1 634/4885JAK1 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.